As semaglutide and tirzepatide prescriptions multiply across diabetes, obesity, and cardiovascular indications, millions of surgical patients now arrive in operating rooms on drugs that fundamentally alter gastric physiology — yet standard pre-operative fasting protocols were designed for a very different patient population. The clinical implications of this mismatch deserve serious attention.
This clinical review, published in Therapeutics and Clinical Risk Management, examines the intersection of GLP-1 receptor agonist pharmacology and perioperative safety. The central concern is delayed gastric emptying: GLP-1 receptor agonists slow gastrointestinal motility, meaning stomach contents may persist even after patients have adhered strictly to conventional nil-by-mouth guidelines. The authors systematically evaluate evidence on aspiration pneumonia risk, noting that while retrospective outcome studies have not consistently demonstrated elevated rates of aspiration events in GLP-1 users, this finding carries important caveats — aspiration pneumonia is a rare endpoint, most available data are retrospective with residual confounding, and definitions of "residual gastric contents" vary considerably across studies. Beyond aspiration, the framework addresses less-discussed concerns: altered oral drug absorption in the perioperative window and the glycemic and metabolic consequences of abruptly interrupting GLP-1 therapy around surgery. Gastric ultrasonography is highlighted as a selective bedside risk-mitigation tool for identifying high-risk individuals.
This review is clinically timely but methodologically incremental — it synthesizes existing evidence rather than generating new primary data. Its most practical contribution is the pharmacist-led individualization framework, which fills a real coordination gap. Anesthesiologists, surgeons, and primary prescribers rarely communicate systematically about GLP-1 status, last-dose timing, or symptom burden. The review acknowledges divergence among major professional society guidance statements, reflecting genuine uncertainty in the field. For health-conscious adults approaching elective procedures, the broader implication is that medication reconciliation conversations should explicitly include GLP-1 agents, which are still frequently omitted from pre-surgical medication reviews. This is confirmatory and consensus-building work rather than paradigm-shifting, but it addresses a safety gap that is growing faster than the evidence base.